NEKTAR THERAPEUTICSCS
NEKTAR THERAPEUTICSCS
Share · US6402681083 · NKTR · 165417 (XNAS)
Overview Financial Indicators
8,61 USD
-3,69 % -0,33 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
13.06.2025 21:30

Current Prices from NEKTAR THERAPEUTICSCS

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
NKTR
USD
13.06.2025 21:30
8,61 USD
8,75 USD
-1,60 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % -15,59 % -19,72 % -34,56 % -43,17 % -50,94 % -57,98 %

Company Profile for NEKTAR THERAPEUTICSCS Share

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Invested Funds

The following funds have invested in: NEKTAR THERAPEUTICSCS invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
95,85
Percentage (%)
0,22 %

Company Data

Name NEKTAR THERAPEUTICSCS
Company Nektar Therapeutics
Symbol NKTR
Website https://www.nektar.com
Primary Exchange XNAS NASDAQ
WKN 165417
ISIN US6402681083
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Mr. Howard W. Robin
Market Capitalization 92 Mio
Country United States of America
Currency USD
Employees 0,1 T
Address 455 Mission Bay Boulevard South, 94158 San Francisco
IPO Date 2018-07-18

Stock Splits

Date Split
09.06.2025 1:15
23.08.2000 2:1

Ticker Symbols

Name Symbol
Frankfurt ITH.F
London 0UNL.L
NASDAQ NKTR

More Shares

Investors who NEKTAR THERAPEUTICSCS hold also have the following shares in their portfolio:
AIS-AM.MSCI USA DLC
AIS-AM.MSCI USA DLC ETF
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
DEKALUX-EUROPA TF (A)
DEKALUX-EUROPA TF (A) Fund
ELECTRONIC ARTS INC
ELECTRONIC ARTS INC Share
INTEL CORP
INTEL CORP Share
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Share
MICROSOFT CORP
MICROSOFT CORP Share
NXP SEMICONDUCTORS NV
NXP SEMICONDUCTORS NV Share
QNB FINANCE LIMITED 4.68% SEN UNS NTS 10/08/33
QNB FINANCE LIMITED 4.68% SEN UNS NTS 10/08/33 Bond
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
WISDOMTREE.HMS.Z12/UN.XAU
WISDOMTREE.HMS.Z12/UN.XAU ETC
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025